



## Supplementary Information




**Fig. S1. Latrunculin B treatment in oocytes.**

Immunostaining analysis of oocytes after being treated with latrunculin B. The oocytes were treated with 10  $\mu$ M latrunculin B in TYH medium for 1 hour, then incubated with 0.5  $\mu$ g ml<sup>-1</sup> MZ3-FITC (CD9: green), 0.5  $\mu$ g ml<sup>-1</sup> TH6-Alexa647 (JUNO: red), 1  $\mu$ g ml<sup>-1</sup> GoH3-Alexa546 (Integrin  $\alpha$ 6: purple) and 1  $\mu$ g ml<sup>-1</sup> Hoechst 33342 (nucleus: blue). Two different angles are shown of a latrunculin B-treated oocyte. Scale bars: 10  $\mu$ m.




**Fig. S2. Immunofluorescence of oocytes with antibodies against membrane-anchored proteins.**

WT, *Cd9*<sup>-/-</sup> and *Juno*<sup>-/-</sup> oocytes were incubated in TYH medium with 1  $\mu\text{g ml}^{-1}$  GoH3-Alexa546 (Integrin  $\alpha 6$ : **A**), 5  $\mu\text{g ml}^{-1}$  HMb1-1-FITC (Integrin  $\beta 1$ : **B**), 2  $\mu\text{g ml}^{-1}$  CD315 antibody (EWI-F: **C**, visualization: Alexa Fluor 647-labeled  $\alpha$ -Sheep IgG), 5  $\mu\text{g ml}^{-1}$  Eat2 (CD81: **D**, visualization: Alexa Fluor 647-labeled  $\alpha$ -Armenian hamster IgG) and 1  $\mu\text{g ml}^{-1}$  RIKO-3-Alexa647 (CD55: **E**). Scale bars: 10  $\mu\text{m}$ .



**Fig. S3. Methyl-β-cyclodextrin (MβCD) treatment in oocytes.**


(A) Cholesterol depletion of zona-free oocytes. The zona-free oocytes were incubated with different concentrations of MβCD for 30 min at 37°C. In this assay, all oocytes survived in the 2 mM MβCD treatment only. Scale bars, 100 μm. (B) Immunostaining analysis of oocytes after treatment with MβCD. The oocytes were incubated with 0.5 μg ml<sup>-1</sup> MZ3-FITC (CD9: green), 0.5 μg ml<sup>-1</sup> TH6-Alexa647 (JUNO: red), 1 μg ml<sup>-1</sup> GoH3-Alexa546 (Integrin α6: purple) and 1 μg ml<sup>-1</sup> Hoechst 33342 (nucleus: blue) in TYH medium for 90 min, then treated with 2 μM MβCD in FHM medium for 30 min. Two different angles are shown of a MβCD-treated WT and *Cd9*<sup>-/-</sup> oocytes. Scale bars: 10 μm.



**Fig. S4. Original western blot images.**


Entire images of blots of Fig. 2B. Blots were incubated with  $1 \mu\text{g ml}^{-1}$  12A5 (JUNO: **A**),  $1 \mu\text{g ml}^{-1}$  EM-04 (CD9: **B**) and  $1 \mu\text{g ml}^{-1}$  5A12 (GAPDH: **C**).





**Movie 1. FRAP analysis of JUNO in *Cd9<sup>-/-</sup>* oocyte, related to Fig. 5B.**

Oocytes are shown in Gray Scale (upper panels) and Fire LUT (bottom panels) of Fiji. The JUNO fluorescence images were taken at 2 min intervals over 58 min after photobleaching the cortical actin cap region.



**Movie 2. FRAP analysis of CD55 in *Cd9<sup>-/-</sup>* oocyte, related to Fig. 5B.**

Oocytes are shown in Gray Scale (upper panels) and Fire LUT (bottom panels) of Fiji. The CD55 fluorescence images were taken at 2 min intervals over 58 min after photobleaching the cortical actin cap region.